4D Molecular Therapeutics Investor Day 2026 - 4D MOLECULAR THERAPEUTICS INC

Explicit Guidance:

• Clinical Readouts: Phase 3 "Forefront 1" data expected Q1/Q2 2027; Phase 3 "Forefront 2" data expected in the second half of 2027.
• Financial Runway: Current cash position supports operations into the second half of 2028.
• Treatment Burden Reduction (Projected):
  • Phase 2b results indicate 78% reduction in treatment burden vs. idealized aflibercept q8w; 87% reduction in recently diagnosed subgroups.
  • Target to achieve "injection-free" status for a significant portion of patients for many years, potentially lifelong.
• Commercialization Reimbursement Model: Anticipates maintaining the "buy and bill" model (Medicare Part B) similar to current anti-VEGF therapies for the foreseeable future (2026–2028).

Business-Segment Outlook:

• Product (4150): Positioned as a "backbone therapy" for all wet AMD patients (naive and treated), targeting continuous lifelong disease control via a single intravitreal injection.
• Patient Segments: Initial commercial focus on "high-need" patients (requiring ≥8 injections/year, ~25% of treated eyes), expanding over time to moderate (45%) and low-burden patients.
• Bilateral Treatment: Regulatory requirements mandate a fellow-eye study; commercial launch expected to support bilateral administration (30–40% of patients have bilateral disease) with timing estimated 3–6 months after the first eye's corticosteroid taper concludes.
• Pipeline: Phase 3 programs (Forefront 1 and 2) are fully enrolled (523 and 531 patients, respectively), with a design emphasizing treatment-naive populations to maximize label breadth.

Market and Competitive Outlook:

• Market Size: Global wet AMD/DME market valued at ~$16B; U.S. estimated at 800,000 treated eyes currently, growing to ~900,000 eyes by 2030.
• Adoption Trajectory:
  • Year 1: Low market penetration due to "anonymous" J-code and reimbursement uncertainty; focus on high-need and "pure" Medicare patients (approx. 40% of market).
  • Years 2–4: Expected uptick following establishment of permanent J-codes (anticipated ~9 months post-approval) and payer confidence; potential usage in 20–25% of clinic patient base.
  • Long-term: Shift toward broad adoption across treatment-naive populations; demand driven by patient preference for injection-free status.
• Competitive Differentiation: Unique value proposition of "continuous disease control" vs. finite durability of current bolus therapies (e.g., brolucizumab, faricimab). 0% of existing/comparable competitors offer potential for injection-free status or lifelong expression.

Macro / Industry Outlook:

• Payer Dynamics: 90% of wet AMD patients are covered by Medicare (37% traditional, 51% Medicare Advantage). Payers acknowledge unmet needs (87% seek improved therapy) and view gene therapy as the most promising solution (71% support).
• Reimbursement Environment: 3 of 4 payers acknowledge limitations of current therapies; 100% agree on the goal of ongoing vision protection.
• Operational Economics: Current "buy and build" model suffers from "value erosion" due to patient attrition (~40% drop-out by Year 1) and administrative overhead. 4150 is projected to capture upfront value and reduce operational workload (10 visits/injections vs. ~300 over 5 years for 10 patients).
• Safety Perception: Management and KOLs anticipate safety profile will be acceptable, managing expected mild, transient inflammation via a 20-week corticosteroid taper. Cataract development is viewed as an acceptable trade-off given cataract surgery is "inevitable" and replaceable.

Strategic Initiatives:

• Phase 3 Execution: Two randomized, controlled, non-inferiority trials (Forefront 1: 100% naive; Forefront 2: up to 40% previously treated) designed to align with regulatory pathways (RMAT with FDA, PRIME with EMA).
• Target Product Profile: Single routine injection, low dose (3E10), retinotropic vector (R100), and 20-week prophylactic steroid regimen.
• Commercial Infrastructure: Leveraging "buy and build" model for seamless clinic integration without surgical requirements; reliance on KOL engagement (ASRS, etc.) to drive adoption.
• Capacity Optimization: Aiming to alleviate clinic capacity constraints (currently 100+ patients per clinic day) by reducing injection frequency and visit burden.

Risks and Headwinds to Outlook:

• Regulatory/Approval: No guarantee of trial success, regulatory approval, or commercialization; Phase 3 outcomes (Week 52 BCVA) are the primary hurdle.
• Safety: Potential for inflammation or unexpected adverse events, though management expects manageable, transient effects limited to the initial 28 weeks.
• Reimbursement Uncertainty: Timeline for permanent J-codes and payer consensus on pricing/value proposition remains a critical variable for adoption speed.
• Patient Adherence: While 4150 reduces burden, patient drop-out due to non-compliance with the 20-week steroid taper or other health issues (e.g., hospitalization) remains a risk, though less severe than chronic injection schedules.
• Bilateral Dosing: Commercial timing for fellow-eye treatment depends on physician discretion and safety data from the ongoing fellow-eye study.

Management Tone on the Future:

• Confidence: High confidence in "great success in 2027 and beyond" based on Phase 1/2 data, robust Phase 3 design, and alignment of stakeholders (patients, physicians, payers).
• Sentiment: Describes the opportunity as a "paradigm shift" and "monumental," with KOLs expressing "unbridled enthusiasm" and patients showing "off the charts" receptivity.
• Strategic Hedges: Emphasizes that 4150 is a "backbone therapy" intended for "all" patients eventually, not just the most severe, but acknowledges initial uptake will likely target high-burden cohorts until reimbursement is solidified.
• Operational Outlook: Views the "buy and build" model as a net positive for clinics, enhancing rather than eroding value by capturing lifetime upfront reimbursement and reducing overhead.

Miscellaneous:

• Target Product Profile (TPP): Continuous disease control, 24/7/365 treatment expression, single injection, potential for lifelong injection-free status, and significant reduction in treatment burden.
• Key Opinion Leader (KOL) Sentiment: unanimous agreement on the need for a paradigm shift; physicians anticipate starting with high-need patients but broadening to all treated eyes within 3–5 years.
• Patient Motivation: 90% of patients want to ask physicians about 4150; primary drivers are preservation of independence and avoidance of blindness.